AzTrials
AzTrials

Prosthesis UserNCT04023578

An Investigation of Functional Improvements in the RHEO KNEE Compared to Hydraulic Microprocessor Controlled Knees (MPKs)

A study testing RHEO KNEE XC in people with Prosthesis User and Amputation, run by Össur Iceland ehf at 4 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study was to evaluate the mobility, perceived safety and functioning of unilateral transfemoral (TF) amputees using the Rheo Knee XC compared to their existing prosthetic knee (RHEO KNEE II, III or Genium, X2 or X3) after 3 weeks of use. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Prosthesis User, Amputation
What is being tested?
RHEO KNEE XC
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
4 sitesUnited States
Study dates
30 Jun 2015to 4 Aug 2015
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Cognitive ability to understand all instructions and questionnaires in the study;
  • Unilateral kneedisartic or transfemoral users fitted to Rheo Knee II,III Genium or X2 or X3
  • Willing and able to participate in the study and follow the protocol
  • Confident prosthetic users for more than 3 months
  • Older than 18 years

Who cannot join

  • 50Kg> body weight > 136Kg
  • Users with cognitive impairment
  • Users not understanding the function of the knee
  • Users not able to charge the battery

Trial locations and contacts

4 sites in 1 country.

United States4 sites
  • Methodist Rehabilitation Center

    Flowood, Mississippi, 39232

  • Baker Orthotics & Prosthetics

    Fort Worth, Texas, 76104

  • Ossur Americas, Florida Gait lab

    Orlando, Florida, 32812

  • Virginia Prosthetics & Orthotics

    Roanoke, Virginia, 24012

Other trials in United States

About this study

Official title: Mobility and Perceived Functioning of Unilateral Transfemoral Amputees, Comparison of Hydraulic and Magneto-rheologic Microprocessor Controlled Knees.

The aim of this study was to evaluate the mobility, perceived safety and functioning of unilateral transfemoral (TF) amputees using the Rheo Knee XC compared to their existing prosthetic knee (RHEO KNEE II, III or Genium, X2 or X3) after 3 weeks of use.

The primary objective of the study was to determine/investigate whether unilateral (TF) amputees can apply and benefit from the stair ascent function of the Rheo Knee XC and compare the stair ascent function and automatic cycling detection of the Rheo Knee XC to hydraulic microprocessor controlled knees (MPK-HY).

Read more

The testing was conducted in a non-blinded, multicenter, prospective within subject comparison, with a subgroup analysis with Magneto-rheologic microprocessor controlled knees (MPK-MR) subgroup and MPK-HY subgroup comparing to the Rheo knee XC.

A convenience sample of 15 transfemoral amputee users was recruited at 4 study sites.

Inclusion criteria:

  • Cognitive ability to understand all instructions and questionnaires in the study;
  • Unilateral knee-disarticulated or transfemoral users fitted to Rheo Knee II,III or Genium
  • Willing and able to participate in the study and follow the protocol
  • Confident prosthetic users for more than 3 months
  • Older than 18 years Exclusion Criteria
  • Patients with the following characteristics are not eligible for study entry:
  • 50Kg> body weight > 136Kg
  • Users with cognitive impairment
  • Users not understanding the function of the knee
  • Users not able to charge the battery Testing was conducted between June and August 2015 in four US locations. Participants visited the study location twice, for approximately 3 hours per visit. First time for the baseline measure and initial fitting and secondly after 3 weeks of accommodation on the Rheo knee XC, performing the same measures as for the baseline. Measures included 6 minute walk test with Borg scale CR pre and post, L-test, stair assessment index, stair and bicycle evaluation and Prosthesis evaluation questionnaire mobility section (PEQ MS12/5)

For statistics repeated measures analysis of variance (ANOVA) comparing baseline to 3 week follow up were performed.

Read the detailed description

Recruiting and participants:

A convenience sample of 15 transfemoral amputee users was recruited at 4 study sites. Potential subjects were identified from the customer base of study sites, local investigators evaluated , based on previous experience of interaction with and servicing of patients, if a potential participant is cognitively capable. If a potential participant fitted the inclusion and exclusion criteria the local investigator (CPO-Certified prosthetist/orthotist) contacted them via telephone. During the telephone call the investigator verified if they were interested in participating in the study. If interest was expressed and eligibility criteria was met an appointment was made for enrollment in the study. Informed consent was obtained from all participants at the beginning of the first visit, prior to clinical testing and prosthetic fitting.

Setting:

Testing was conducted in four US locations with daily mean temperature during the testing period between 79.3 to 85.3 degrees Fahrenheit, Fort Worth (Baker orthotics \& prosthetics), Jackson (Methodist Rehabilitation Center), Roanoke (Virginia Prosthetics \& orthotics) and Orlando (Ossur facility, Florida gait lab) . Participants had to visit the study location twice, for approximately 3 hours per visit. First time for the baseline measure and initial fitting and secondly after 3 weeks of accommodation on the Rheo knee XC, performing the same measures as for the baseline. No standard exists for follow up time needed for amputees to adapt to a new prosthesis however, a follow up time of at least 3 weeks is widely used and considered sufficient for functional comparison.

All users used their existing sockets throughout the testing without modifications. One group consisted of 9 previous MPK-magnetorheologic (MPK-MR), Rheo knee II and III, users and the second group of 4 previous MPK-hydraulic knee (MPK-HY), Genium, users. By maintaining alignment and foot choice in the previous Rheo knee group confounding factors could be minimized. The previous MPK-HY was provided with an alignment offset adapter and a consistent foot choice, XC Vari-Flex, at initial fitting. The load line was controlled to be equal prior and post initial fitting. During the initial fitting the MPK-HY users which were new to the XC Vari-Flex had to undergo an evaluation for the foot stiffness as defined by the manufacturer (Ossur ehf). Foot configuration had to be rated acceptable or better with all users that were provided with a XC Vari-Flex.

13 users completed a 3 week evaluation in a multi-center trial with the RHEO KNEE XC at which point they performed Borg Scale CR 10 pre, 6MWT, Borg Scale CR 10 post, L-Test, stair and bicycle evaluation and prosthesis evaluation quesionnaire mobility section) PEQ MS 12/5) on functional ability and prosthesis satisfaction in this order.

The Borg Scale CR 10 is an accepted and reliable psychophysical score which has been used to report on the perceived level of exertion in lower limb amputees. The 6MWT has shown to be a reliable measure in amputees and differentiate among functional levels with a minimum detectable change for unilateral trans-tibial and transfemoral found at 45m. The L-Test is a valid indicator for functional mobility and showed high intraclass correlation, interrater reliability, and minimal bias upon retesting with a moderate correlation to self-reports like the PEQ MS 12/522 which itself is a reliable and valid measure for lower limb amputee assessing psychometric properties.

Ambulating stairs was evaluated as a timed parameter split up in ascending and descending. An observer score/SAI for the gait quality, and a user score/self-report with a 5 point scale (Please rate your ability when using the prosthesis: unable=0, highly difficult=1, moderate difficulty=2, little difficulty=3, no problems=4) similar to the PEQ MS 12/5 scores described by Franchignoni et. al.22 was used. The Rheo Knee XC stair mode can be entered by flexing the hip of the amputated side faster and to a higher degree than in typical walking. The Rheo knee XC will then maintain a flexed position to allow the user to position the foot onto the next stair case. The Genium requires the amputee to stop in front of the stairs and initiate a fast movement into hip-hyperextension to allow the knee to maintain a flexed position. For adapting these two different techniques each user was given 30min training time with instructions to get familiar with the stairs and the operation of the knee in specific location. Equal time was given after initial fitting which was important to the previous MPK-MR knee users who have not used the stair mode before. For the bicycle evaluation the same 5 point scale for the self-report assessment was applied to report on 2 questions: Rate your ability to ride the bicycle and rate your ability to stop the bike with the prosthetic side down.

Being tested
RHEO KNEE XC

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RHEO KNEE XCDevice

    Microprocessor controlled knee using Magneto-Rheologic techonology.

Study groups in NCT04023578
Study groupRoleWhat they receive
Rheo Knee XCExperimentalAmputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
Receives: Device: RHEO KNEE XC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 6 Minute Walk Test (6MWT)

    The 6MWT is simply a record of the distance traveled by a given patient at his or her self-selected walking speed over a period of six minutes. All that is required is a stopwatch and a walking corridor or track of known distance. Those administering the test should avoid walking with or in front of test subjects to avoid pacing individuals outside of their self-selected walking speed.

    The outcome of the test is the distance walked in 6 minutes, in meters.

    Measured: Measured at baseline and after 3 weeks follow up.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2019
  2. Study start30 Jun 2015
  3. Primary completion4 Aug 2015
  4. Study completion4 Aug 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04023578
Sponsor's protocol ID
CIP-P197
Status last verified
Mar 2020
First submitted
16 Jul 2019
Last updated
6 Apr 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Hafner BJ, Willingham LL, Buell NC, Allyn KJ, Smith DG. Evaluation of function, performance, and preference as transfemoral amputees transition from mechanical to microprocessor control of the prosthetic knee. Arch Phys Med Rehabil. 2007 Feb;88(2):207-17. doi: 10.1016/j.apmr.2006.10.030.

    PubMed 17270519
  • Starholm IM, Gjovaag T, Mengshoel AM. Energy expenditure of transfemoral amputees walking on a horizontal and tilted treadmill simulating different outdoor walking conditions. Prosthet Orthot Int. 2010 Jun;34(2):184-94. doi: 10.3109/03093640903585016.

    PubMed 20141493
  • Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health. 1990;16 Suppl 1:55-8. doi: 10.5271/sjweh.1815.

    PubMed 2345867
  • Gailey RS, Roach KE, Applegate EB, Cho B, Cunniffe B, Licht S, Maguire M, Nash MS. The amputee mobility predictor: an instrument to assess determinants of the lower-limb amputee's ability to ambulate. Arch Phys Med Rehabil. 2002 May;83(5):613-27. doi: 10.1053/apmr.2002.32309.

    PubMed 11994800
  • Deathe AB, Miller WC. The L test of functional mobility: measurement properties of a modified version of the timed "up & go" test designed for people with lower-limb amputations. Phys Ther. 2005 Jul;85(7):626-35.

    PubMed 15982169
  • Franchignoni F, Monticone M, Giordano A, Rocca B. Rasch validation of the Prosthetic Mobility Questionnaire: A new outcome measure for assessing mobility in people with lower limb amputation. J Rehabil Med. 2015 May;47(5):460-5. doi: 10.2340/16501977-1954.

    PubMed 25783231
  • Resnik L, Borgia M. Reliability of outcome measures for people with lower-limb amputations: distinguishing true change from statistical error. Phys Ther. 2011 Apr;91(4):555-65. doi: 10.2522/ptj.20100287. Epub 2011 Feb 10.

    PubMed 21310896
  • Franchignoni F, Giordano A, Ferriero G, Orlandini D, Amoresano A, Perucca L. Measuring mobility in people with lower limb amputation: Rasch analysis of the mobility section of the prosthesis evaluation questionnaire. J Rehabil Med. 2007 Mar;39(2):138-44. doi: 10.2340/16501977-0033.

    PubMed 17351696

Questions about this trial

What is this clinical trial studying?

A study testing RHEO KNEE XC in people with Prosthesis User and Amputation, run by Össur Iceland ehf at 4 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Mar 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

6 Minute Walk Test (6MWT) (time frame: Measured at baseline and after 3 weeks follow up.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04023578, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in